Press release
Severe Asthma Market Growth, Trends, Consumer Demand and Key Opportunities
Severe Asthma Market
Asthma is a chronic respiratory disease affecting over 260 million people worldwide, and severe asthma represents the most challenging subset. Characterized by frequent exacerbations, reduced lung function, and resistance to standard therapies, severe asthma significantly diminishes quality of life and increases healthcare costs.
The Severe Asthma Market is expanding rapidly as biologic therapies, precision medicine, and digital innovations reshape treatment pathways. Between 2024 and 2034, the market is expected to experience strong growth, supported by rising disease prevalence, an aging patient base, and continuous biopharmaceutical innovation.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71482
Market Overview
• Market Size 2024: Estimated at USD 8.9 billion
• Forecast 2034: Projected to reach USD 21.4 billion
• CAGR (2024-2034): ~9.1%
Key Highlights
• Biologic therapies (anti-IgE, anti-IL-5, anti-IL-4R) are transforming severe asthma treatment.
• Increasing prevalence of asthma due to urbanization, pollution, and lifestyle changes.
• Rising adoption of digital tools such as smart inhalers and mobile health platforms.
• Strong R&D pipeline focusing on gene therapy and personalized treatments.
Segmentation Analysis
By Drug Class
• Biologics (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab)
• Corticosteroids (inhaled and systemic)
• Bronchodilators (LABA, LAMA)
• Leukotriene Modifiers
• Others (theophylline, immunomodulators)
By Therapy Type
• Monotherapy
• Combination Therapy (ICS/LABA, ICS/LAMA, biologics + inhaled therapies)
By Route of Administration
• Inhalation (metered-dose inhalers, dry powder inhalers, nebulizers)
• Subcutaneous/Intravenous (biologics)
• Oral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End User
• Hospitals
• Pulmonology Clinics
• Ambulatory Care Centers
• Homecare Settings
Summary:
The market is shifting strongly toward biologics and combination therapies, while inhaled corticosteroids and bronchodilators remain standard of care for most patients. Subcutaneous administration is growing rapidly due to the success of biologics.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71482/severe-asthma-market
Regional Analysis
North America
• Largest market share in 2024.
• High biologic adoption rates and advanced healthcare infrastructure.
• U.S. leads with strong presence of AstraZeneca, Regeneron/Sanofi, and GSK.
Europe
• Germany, France, and the UK driving growth with biologic uptake.
• EU initiatives supporting precision medicine and digital asthma programs.
• Increasing focus on reducing hospitalization costs through early intervention.
Asia-Pacific
• Fastest-growing region, CAGR ~10.5%.
• High patient base in China, India, and Japan.
• Rapid adoption of biologics in Japan and South Korea.
• Expanding use of digital asthma management apps and homecare devices.
Latin America
• Brazil and Mexico lead the market.
• Limited biologic adoption due to cost barriers, but government programs expanding access.
Middle East & Africa
• Smaller share but steady growth in GCC countries.
• Rising investments in hospital infrastructure and specialist clinics.
• Access challenges persist in low-income regions.
Summary:
While North America and Europe dominate today, Asia-Pacific is emerging as the fastest-growing region, driven by a large patient pool and rising biologic adoption.
Market Dynamics
Key Growth Drivers
• Rising global prevalence of asthma, particularly severe cases.
• Increasing adoption of biologic therapies targeting IgE and interleukins.
• Expansion of digital health solutions like smart inhalers and remote monitoring.
• Growing emphasis on precision medicine and genetic research.
Key Challenges
• High cost of biologics, limiting affordability.
• Patient non-compliance with inhaled therapies.
• Uneven access to advanced treatments in emerging economies.
Latest Trends
• Launch of next-generation biologics with broader patient applicability.
• Integration of AI-driven asthma monitoring platforms.
• R&D in gene therapy and cell-based therapies for long-term management.
• Growing focus on eco-friendly inhalers to meet sustainability goals.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71482
Competitor Analysis
Major Players
• AstraZeneca plc - Fasenra (benralizumab), Tezspire (tezepelumab).
• GlaxoSmithKline plc (GSK) - Nucala (mepolizumab).
• Novartis AG - Xolair (omalizumab, co-developed with Roche).
• Sanofi & Regeneron - Dupixent (dupilumab).
• Teva Pharmaceutical Industries - Cinqair (reslizumab).
• Boehringer Ingelheim - Broad inhaler portfolio, R&D in biologics.
• Amgen Inc. - Partnered in biologic development.
• Chiesi Farmaceutici - Specialty inhaler solutions.
• Cipla Ltd. - Generic asthma therapies in emerging markets.
• Mylan/Viatris - Generics and affordable respiratory drugs.
Competitive Summary:
The severe asthma market is highly competitive, with AstraZeneca, GSK, Sanofi/Regeneron, and Novartis dominating the biologics space. Emerging competition from biosimilars and generic inhaler manufacturers is expected to increase affordability in the long run.
Conclusion
The Severe Asthma Market is projected to grow from USD 8.9 billion in 2024 to USD 21.4 billion by 2034, at a robust CAGR of 9.1%. Growth will be driven by rising prevalence, biologic adoption, and innovations in digital asthma care.
While high treatment costs and adherence challenges persist, the expansion of precision medicine, gene therapy research, and AI-driven monitoring tools presents significant opportunities. Asia-Pacific is expected to be the fastest-growing region, while North America and Europe continue to lead in biologic approvals and adoption.
Key Takeaway: Companies focusing on biologics, precision medicine, and digital asthma management will be best positioned to capture long-term growth in the severe asthma market.
This report is also available in the following languages : Japanese (重症喘息市場), Korean (중증 천식 시장), Chinese (严重哮喘市场), French (Marché de l'asthme sévère), German (Markt für schweres Asthma), and Italian (Mercato dell'asma grave), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71482
Our More Reports:
Peripheral T-Cell Lymphoma (PTCL) Market
https://exactitudeconsultancy.com/reports/71610/peripheral-t-cell-lymphoma-ptcl-market
Sezary Syndrome (SS) Market
https://exactitudeconsultancy.com/reports/71612/sezary-syndrome-ss-market
Anaplastic large cell lymphoma (ALCL) Market
https://exactitudeconsultancy.com/reports/71614/anaplastic-large-cell-lymphoma-alcl-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Asthma Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4168126 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for Asthma
Evolving Market Trends In The Asthma Spacers Industry: Smart Inhaler Devices Rev …
The Asthma Spacers Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Asthma Spacers Market Size During the Forecast Period?
The asthma spacers market has grown steadily, forecasted to rise from $1.88 billion in 2024 to $2.01 billion in 2025 at a CAGR…
Asthma Relief Reimagined: Trends Driving Asthma Spacer Innovation
The Business Research Company recently released a comprehensive report on the Global Asthma Spacers Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Asthma Warning Sensors Market Connected Care for Asthma: How Warning Sensors Imp …
Asthma Warning Sensors Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Warning Sensors Market Size, Share & Trends Analysis Report By Type (Wearable v/s Non-Wearable), By Technology (AI, IoT, Machine Learning, Others), By Parameter Measured (FEV1 v/s Peak Flow), By End User (Hospitals & Clinics v/s Homecare)- Market…
Asthma Spacers Market Optimizing Asthma Treatment: How Spacers are Improving Del …
Asthma Spacers Market Assessment worth $ 2.47 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Spacers Market- by Product (Space Chamber Plus, A2A Spacer, Flo-Tone CR, Able Spacer, AeroChamber, Volumatic, Vortex, OptiChamber), Application (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get a free sample copy of…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Asthma Monitoring Devices Market - Revolutionizing Asthma Care: Elevate Monitori …
Newark, New Castle, USA: The "Asthma Monitoring Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Asthma Monitoring Devices Market: https://www.growthplusreports.com/report/asthma-monitoring-devices-market/8697
This latest report researches the industry structure,…
